Cargando…

Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers

About 5% of patients undergoing radiotherapy (RT) develop RT-related side effects. To assess individual radiosensitivity, we collected peripheral blood from breast cancer patients before, during and after the RT, and γH2AX/53BP1 foci, apoptosis, chromosomal aberrations (CAs) and micronuclei (MN) wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Durdik, Matus, Markova, Eva, Kosik, Pavol, Vigasova, Katarina, Gulati, Sachin, Jakl, Lukas, Vrobelova, Katarina, Fekete, Marta, Zavacka, Ingrid, Pobijakova, Margita, Dolinska, Zuzana, Belyaev, Igor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136353/
https://www.ncbi.nlm.nih.gov/pubmed/37189740
http://dx.doi.org/10.3390/biomedicines11041122
_version_ 1785032197833490432
author Durdik, Matus
Markova, Eva
Kosik, Pavol
Vigasova, Katarina
Gulati, Sachin
Jakl, Lukas
Vrobelova, Katarina
Fekete, Marta
Zavacka, Ingrid
Pobijakova, Margita
Dolinska, Zuzana
Belyaev, Igor
author_facet Durdik, Matus
Markova, Eva
Kosik, Pavol
Vigasova, Katarina
Gulati, Sachin
Jakl, Lukas
Vrobelova, Katarina
Fekete, Marta
Zavacka, Ingrid
Pobijakova, Margita
Dolinska, Zuzana
Belyaev, Igor
author_sort Durdik, Matus
collection PubMed
description About 5% of patients undergoing radiotherapy (RT) develop RT-related side effects. To assess individual radiosensitivity, we collected peripheral blood from breast cancer patients before, during and after the RT, and γH2AX/53BP1 foci, apoptosis, chromosomal aberrations (CAs) and micronuclei (MN) were analyzed and correlated with the healthy tissue side effects assessed by the RTOG/EORTC criteria. The results showed a significantly higher level of γH2AX/53BP1 foci before the RT in radiosensitive (RS) patients in comparison to normal responding patients (NOR). Analysis of apoptosis did not reveal any correlation with side effects. CA and MN assays displayed an increase in genomic instability during and after RT and a higher frequency of MN in the lymphocytes of RS patients. We also studied time kinetics of γH2AX/53BP1 foci and apoptosis after in vitro irradiation of lymphocytes. Higher levels of primary 53BP1 and co-localizing γH2AX/53BP1 foci were detected in cells from RS patients as compared to NOR patients, while no difference in the residual foci or apoptotic response was found. The data suggested impaired DNA damage response in cells from RS patients. We suggest γH2AX/53BP1 foci and MN as potential biomarkers of individual radiosensitivity, but they need to be evaluated with a larger cohort of patients for clinics.
format Online
Article
Text
id pubmed-10136353
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101363532023-04-28 Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers Durdik, Matus Markova, Eva Kosik, Pavol Vigasova, Katarina Gulati, Sachin Jakl, Lukas Vrobelova, Katarina Fekete, Marta Zavacka, Ingrid Pobijakova, Margita Dolinska, Zuzana Belyaev, Igor Biomedicines Article About 5% of patients undergoing radiotherapy (RT) develop RT-related side effects. To assess individual radiosensitivity, we collected peripheral blood from breast cancer patients before, during and after the RT, and γH2AX/53BP1 foci, apoptosis, chromosomal aberrations (CAs) and micronuclei (MN) were analyzed and correlated with the healthy tissue side effects assessed by the RTOG/EORTC criteria. The results showed a significantly higher level of γH2AX/53BP1 foci before the RT in radiosensitive (RS) patients in comparison to normal responding patients (NOR). Analysis of apoptosis did not reveal any correlation with side effects. CA and MN assays displayed an increase in genomic instability during and after RT and a higher frequency of MN in the lymphocytes of RS patients. We also studied time kinetics of γH2AX/53BP1 foci and apoptosis after in vitro irradiation of lymphocytes. Higher levels of primary 53BP1 and co-localizing γH2AX/53BP1 foci were detected in cells from RS patients as compared to NOR patients, while no difference in the residual foci or apoptotic response was found. The data suggested impaired DNA damage response in cells from RS patients. We suggest γH2AX/53BP1 foci and MN as potential biomarkers of individual radiosensitivity, but they need to be evaluated with a larger cohort of patients for clinics. MDPI 2023-04-07 /pmc/articles/PMC10136353/ /pubmed/37189740 http://dx.doi.org/10.3390/biomedicines11041122 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Durdik, Matus
Markova, Eva
Kosik, Pavol
Vigasova, Katarina
Gulati, Sachin
Jakl, Lukas
Vrobelova, Katarina
Fekete, Marta
Zavacka, Ingrid
Pobijakova, Margita
Dolinska, Zuzana
Belyaev, Igor
Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title_full Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title_fullStr Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title_full_unstemmed Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title_short Assessment of Individual Radiosensitivity in Breast Cancer Patients Using a Combination of Biomolecular Markers
title_sort assessment of individual radiosensitivity in breast cancer patients using a combination of biomolecular markers
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136353/
https://www.ncbi.nlm.nih.gov/pubmed/37189740
http://dx.doi.org/10.3390/biomedicines11041122
work_keys_str_mv AT durdikmatus assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT markovaeva assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT kosikpavol assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT vigasovakatarina assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT gulatisachin assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT jakllukas assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT vrobelovakatarina assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT feketemarta assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT zavackaingrid assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT pobijakovamargita assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT dolinskazuzana assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers
AT belyaevigor assessmentofindividualradiosensitivityinbreastcancerpatientsusingacombinationofbiomolecularmarkers